Repeated dose toxicity study of CpG 2395 and summary to safety charac-teristics of CpG ODNs
10.3969/j.issn.1000-484X.2025.11.029
- VernacularTitle:CpG 2395重复给药毒性试验及对CpG ODNs安全性特征的汇总
- Author:
Yuanyuan WANG
1
;
Shihao CUI
;
Ming ZHOU
;
Yuchao GU
Author Information
1. 中国海洋大学医药学院,青岛 266003
- Publication Type:Journal Article
- Keywords:
CpG 2395;
CpG ODNs;
Oligonucleotide;
Vaccine adjuvant;
Immunotoxicity
- From:
Chinese Journal of Immunology
2025;41(11):2730-2740
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate repeated dose toxicity of CpG 2395 and summarize common safety characteristics of CpG ODNs.Methods:Rats were randomly divided into 7 groups and injected with different doses of CpG 2395,CpG-Alum adjuvant system and normal saline into hindlimb muscles(4 administrations,2 weeks apart).After administration,clinical observations were conducted at different time points,accompanied by other examinations,such as body weight,food consumption,body temperature,hematology,coagulation,clinical chemistry,urinalysis,cytokines,gross pathology and histopathology.Additionally,repeated dose toxicity results of other CpG ODNs were summarized and analyzed.Results:CpG 2395 possessed relevant attributes to induce significant immunostimu-latory effects,and addition of aluminum adjuvants could enhance these processes.Different CpG ODNs had common safety characteris-tics.Relevant symptoms would be mainly alleviated or eliminated without delayed toxicity after end of administrations,and dose-toxicity relationship had been confirmed.Conclusion:CpG 2395 is considered to be safe and controllable at proposed clinical dose,and based on common safety characteristics,possible local and systemic adverse reactions can be predicted in advance before clinical application of CpG 2395.
